Great Point Partners (GPP) has acquired a majority stake in Eutecma, a developer of reusable temperature-controlled packaging solutions for pharmaceutical cold chain logistics.<\/p>\n
<\/p>\n
Established in 2008, Germany-based Eutecma has dedicated itself to developing passive cooling systems that enhance sustainability and efficiency in transportation and logistics.<\/p>\n
It is said to have established itself in the pharmaceutical sector with its patented ICECATCH cooling systems.<\/p>\n
Eutecma\u2019s \u2018retecma\u2019 system fosters a circular economy for its packaging materials through an extensive network of refreshment centres.<\/p>\n
The approach ensures that materials are kept in circulation for longer periods while minimising carbon dioxide emissions.<\/p>\n
GPP vice-president Harrison Johnson said: \u201cEutecma has the opportunity to further expand its global capabilities at a time when there\u2019s growing demand for reusability, cost savings, and new cooling technologies within [the] cold chain.<\/p>\n
\u201cThis investment underscores our dedication to supporting exceptional high-growth healthcare companies that assist in bringing life-saving medicines to patients across the globe.\u201d<\/p>\n
The collaboration also involves Eutecma\u2019s acquisition of Resolvision, a proprietary reuse technology employed at its refreshment centres.<\/p>\n
Through this acquisition, Eutecma intends to broaden its global presence and enhance its offerings in the cold chain packaging sector.<\/p>\n
The partnership is anticipated to further promote sustainable practices within the pharmaceutical industry.<\/p>\n
Eutecma co-founder Florian Zeilfelder said: \u201cWe have successfully created innovative and sustainable cold chain solutions that have proven themselves with well-known pharmaceutical customers.<\/p>\n
\u201cOur work with GPP will advance that mission so we can strategically expand our reach, especially in the US and other geographies around the world.\u201d<\/p>\n
Healthcare investment company\u00a0GPP is currently making new minority and majority private equity investments from GPP IV. The company manages about $1.5bn of capital via its private funds and public biotechnology equity strategy.<\/p>\n
<\/p>\n
<\/p>\n
<\/p>\n
![\"Email](\"https:\/\/www.packaging-gateway.com\/wp-content\/themes\/goodlife-wp-B2B\/assets\/images\/newsletter-new.svg\")
\n <\/div>\nSign up for our daily news round-up!<\/h3>\nGive your business an edge with our leading industry insights.<\/h3>\n<\/p><\/div>\n<\/p><\/div>\n<\/section>\n<\/div>\n
<\/p>\n